Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

ARCA biopharma to study Gencaro in Phase III trial

Gencaro is being developed as a genetically-targeted atrial fibrillation prevention treatment. Credit: BruceBlaus.



  • ARCA biopharma to study Gencaro in Phase III trial

Go Top